CJC-1295 + Ipamorelin

GHRH analog plus selective GHRP combination

Technical datasheetLZH-006

Code: GHRH + GHRP
Half-life: CJC-1295 DAC: ~6-8 d (albumin bound); Ipamorelin: ~2 h
Research route: Subcutaneous (research)
Molecular targets: GHRH-R (CJC-1295) · GHSR-1a / ghrelin receptor (Ipamorelin)
Discovery / disclosure: ConjuChem (CJC-1295, 2005); Novo Nordisk (Ipamorelin, 1998)
Target purity: ≥ 98%
Recommended storage: −20°C, light protected. 2 to 8°C after reconstitution.

Aliases

CJC-1295 DAC + Ipamorelin

Appearance

White lyophilized powder

Solubility

Both soluble in bacteriostatic water

Sequence

CJC-1295: YAibDAIFTQSYRKVLAQLSARKLLQDIMSR-Lys(MPA)-NH2 | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Analysts reviewing the HPLC chromatogram for the current batch — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technician monitoring a stainless steel reactor during scale-up — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Overview

CJC-1295 is a long-acting GHRH analog and Ipamorelin is a highly selective growth hormone releasing peptide. The pair is frequently studied together as a way to model physiological GH pulses.

Pharmacology and mechanism

CJC-1295 acts on the GHRH receptor, broadening GH secretion amplitude. Ipamorelin activates the ghrelin or GHSR-1a receptor, triggering pulse release with minimal effect on cortisol and prolactin.